Is NCT02038673 results overdue?

Yes — results are overdue. Primary completion was 2017-07-19; the FDAAA-801 reporting deadline (2018-07-19) passed 2894 days ago and no results are posted on ClinicalTrials.gov.

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

NCT ID	NCT02038673 ↗
Sponsor	Astellas Pharma Inc (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-07-19 (ACTUAL)
Reporting deadline	2018-07-19 (completion + 365d)
Days overdue	2894
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `767bd6053804ecc6…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02038673. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.